Equities research analysts predict that InflaRx N.V. (NASDAQ:LUMO) will post ($0.67) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for InflaRx’s earnings. InflaRx posted earnings per share of ($2.43) in the same quarter last year, which would suggest a positive year-over-year growth rate of 72.4%. The company is expected to report its next earnings report on Tuesday, August 4th.
According to Zacks, analysts expect that InflaRx will report full year earnings of ($2.86) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($3.73) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for InflaRx.
InflaRx (NASDAQ:LUMO) last issued its earnings results on Thursday, May 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.69. InflaRx had a negative net margin of 3,832.31% and a negative return on equity of 29.17%. The business had revenue of $0.02 million for the quarter.
NASDAQ:LUMO traded down $0.46 on Wednesday, hitting $16.53. The stock had a trading volume of 38 shares, compared to its average volume of 35,380. InflaRx has a 52 week low of $6.74 and a 52 week high of $32.40. The company’s fifty day moving average price is $13.55. The company has a market cap of $140.25 million, a P/E ratio of -2.07 and a beta of 1.55.
InflaRx Company Profile
Lumos Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.